OBJECTIVES: To study the inhibitory effects of plasmid-based siRNA targeting human epidermal growth factor receptor (EGFR) on tumor proliferation and invasion of TJ905 glioblastoma cells. METHODS: Two siRNA expression constructs targeting human EGFR extracellular domain (516-536) and catalytic domain (2400-2420) were transfected into TJ905 cell as mediated by Lipofectamine. Immunofluorescence assay and Western blotting were used to detect EGFR expression. Cell cycle was analyzed by flow cytometry, cell proliferative activity was measured by MTT assay. The expression and enzymatic activity of MMP9 were measured by Western blotting and gelatin zymography. Cell invasive capability was evaluated by Transwell method. RESULTS: The expression of EGFR was knocked-down by 90 and 92, respectively in siRNA constructs transfected groups as indicated by immunofluorescence assay and Western blotting. The flow cytometric analysis showed that the S phase fraction (SPF) was lowered in both siRNAs transfected cells than that in parental cells and the cells transfected with empty vector. Compared to parental cells and the cells transfected with empty vector, the survival rates of glioma cells transfected with the siRNAs dramatically dropped down from the first day after implantation (P<0.05) as indicated by MTT assay. Meanwhile, the expression and enzymatic activity of MMP9 decreased significantly in siRNAs transfected in TJ905 cells, and cell invasive potential was also greatly inhibited in the Transwell study. CONCLUSION: The siRNA expression constructs targeting EGFR could specifically suppress EGFR expression, inhibit cell growth, induce cell cycle arrest and suppress invasion. The plasmid-based siRNA targeting human EGFR approach should be a new strategy for gene therapy of malignant gliomas.
OBJECTIVES: To study the inhibitory effects of plasmid-based siRNA targeting humanepidermal growth factor receptor (EGFR) on tumor proliferation and invasion of TJ905 glioblastoma cells. METHODS: Two siRNA expression constructs targeting humanEGFR extracellular domain (516-536) and catalytic domain (2400-2420) were transfected into TJ905 cell as mediated by Lipofectamine. Immunofluorescence assay and Western blotting were used to detect EGFR expression. Cell cycle was analyzed by flow cytometry, cell proliferative activity was measured by MTT assay. The expression and enzymatic activity of MMP9 were measured by Western blotting and gelatin zymography. Cell invasive capability was evaluated by Transwell method. RESULTS: The expression of EGFR was knocked-down by 90 and 92, respectively in siRNA constructs transfected groups as indicated by immunofluorescence assay and Western blotting. The flow cytometric analysis showed that the S phase fraction (SPF) was lowered in both siRNAs transfected cells than that in parental cells and the cells transfected with empty vector. Compared to parental cells and the cells transfected with empty vector, the survival rates of glioma cells transfected with the siRNAs dramatically dropped down from the first day after implantation (P<0.05) as indicated by MTT assay. Meanwhile, the expression and enzymatic activity of MMP9 decreased significantly in siRNAs transfected in TJ905 cells, and cell invasive potential was also greatly inhibited in the Transwell study. CONCLUSION: The siRNA expression constructs targeting EGFR could specifically suppress EGFR expression, inhibit cell growth, induce cell cycle arrest and suppress invasion. The plasmid-based siRNA targeting humanEGFR approach should be a new strategy for gene therapy of malignant gliomas.
Authors: T Kubiatowski; T Jang; M B Lachyankar; R Salmonsen; R R Nabi; P J Quesenberry; N S Litofsky; A H Ross; L D Recht Journal: J Neurosurg Date: 2001-09 Impact factor: 5.115
Authors: Yun Zhang; Yu-Feng Zhang; Joshua Bryant; Andrew Charles; Ruben J Boado; William M Pardridge Journal: Clin Cancer Res Date: 2004-06-01 Impact factor: 12.531
Authors: Anita Lal; Chad A Glazer; Holly M Martinson; Henry S Friedman; Gary E Archer; John H Sampson; Gregory J Riggins Journal: Cancer Res Date: 2002-06-15 Impact factor: 12.701
Authors: Jens Harborth; Sayda M Elbashir; Kim Vandenburgh; Heiko Manninga; Stephen A Scaringe; Klaus Weber; Thomas Tuschl Journal: Antisense Nucleic Acid Drug Dev Date: 2003-04
Authors: Marina Rolo Pinheiro da Rosa; Aline Semblano Carreira Falcão; Hellen Thais Fuzii; Maria Sueli da Silva Kataoka; André L R Ribeiro; Enrique Boccardo; Adriane Sousa de Siqueira; Ruy G Jaeger; João de Jesus Viana Pinheiro; Sérgio de Melo Alves Júnior Journal: Tumour Biol Date: 2014-08-07
Authors: Monika Witusik-Perkowska; Piotr Rieske; Krystyna Hułas-Bigoszewska; Magdalena Zakrzewska; Robert Stawski; Dominika Kulczycka-Wojdala; Michał Bieńkowski; Ewelina Stoczyńska-Fidelus; Sylwia M Grešner; Sylwester Piaskowski; Dariusz J Jaskólski; Wielisław Papierz; Krzysztof Zakrzewski; Maciej Kolasa; James W Ironside; Paweł P Liberski Journal: J Neurooncol Date: 2010-08-29 Impact factor: 4.130
Authors: Erin B Dickerson; William H Blackburn; Michael H Smith; Laura B Kapa; L Andrew Lyon; John F McDonald Journal: BMC Cancer Date: 2010-01-11 Impact factor: 4.430